Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities (2011 - 2026)

Catalyst Pharmaceuticals' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at -$12.9 million for Q1 2026.

• Quarterly Cash from Financing Activities fell 520.65% year-over-year to -$12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.9 million (down 1330.42% YoY) and the FY2025 annual result came in at -$17.0 million, down 112.08% from the prior year.
• Cash from Financing Activities was -$12.9 million for Q1 2026 at Catalyst Pharmaceuticals, up from -$25.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $141.0 million in Q1 2024 and bottomed at -$25.6 million in Q4 2025.
• A 5-year average of $6.0 million and a median of $149000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 925.0% — and 2024, when it surged 94563.76%.
• Catalyst Pharmaceuticals' Cash from Financing Activities stood at $2.3 million in 2022, then tumbled by 129.52% to -$665000.0 in 2023, then soared by 766.62% to $4.4 million in 2024, then tumbled by 677.04% to -$25.6 million in 2025, then soared by 49.68% to -$12.9 million in 2026.
• Business Quant data shows CPRX's Cash from Financing Activities at -$12.9 million in Q1 2026, -$25.6 million in Q4 2025, and $4.7 million in Q3 2025.